Status:
COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer
Lead Sponsor:
NeuTec Pharma
Conditions:
Cancer of the Breast
Eligibility:
FEMALE
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The study hypothesis is that the addition of Mycograb to docetaxel will improve outcome in advanced carcinoma of the breast.
Detailed Description
Combination therapies that incorporate new agents have demonstrated the potential to improve outcome for patients with metastatic breast carcinoma. Docetaxel has been shown to be a very active drug in...
Eligibility Criteria
Inclusion
- Patients must be female between the ages of 18 to 70 years old.
- Patients must have histologically or clinically confirmed metastatic and/or recurrent breast cancer amenable to treatment with docetaxel.
- Patients must have presence of at least one uni-dimensional measurable lesion with minimal lesion size \> 20 mm at the largest diameter.
- Patients may have had one previous chemotherapy regimen and must not have received prior chemotherapy with docetaxel.
- Patients must have been off all hormonal therapy for at least 2 weeks prior to initiation of therapy.
- Patients must have been off all chemotherapy or radiotherapy regimens for at least 4 weeks prior to initiation of chemotherapy.
- Patients must have a life expectancy of at least 6 months.
- Patients must have a ECOG status of 0, 1 or 2.
- Patients must be willing to complete all procedures and visits as outlined in the protocol.
- Patients must sign an informed consent form.
- Patients must have negative blood test for HIV and hepatitis B and C.
- Female patients of child bearing potential should use an effective method of contraception.
Exclusion
- Patients with brain or meningeal metastases.
- Patients whose only measurable lesion is in the bone.
- Patients with clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, respiratory, neurologic, psychiatric, immunologic, gastrointestinal, hematologic, metabolic or any other condition or laboratory abnormality that in the opinion of the investigator makes the patient unsuitable for participation in the study.
- Patients with history of seizure disorder.
- Patients who have received treatment with any other investigational drug within the preceding one month.
- Patients who are pregnant or breast feeding.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00217815
Start Date
September 1 2005
End Date
October 1 2006
Last Update
July 15 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Chemotherapie Clinic of Medical University Lodz
Lodz, Pabianicka, Poland, 93-513
2
Clinical Hospital Centre Bezanijska Kosa
Bezanijska Kosa Bb, Belgrade, Serbia, 11000
3
Institute For Oncology and Radiology of Serbia
Pasterova 14, Belgrade, Serbia, 11000